|
Results of 2023 Annual General meeting
|
22 May 2023 at 12:40pm
|
|
CEO's AGM address to Securityholders
|
22 May 2023 at 9:00am
|
|
Q1 2023 Results
|
11 May 2023 at 4:05pm
|
|
UBI launches PETRACKR Diabetes product for dogs and cats
|
3 May 2023 at 8:40am
|
|
Change in substantial holding
|
1 May 2023 at 2:55pm
|
|
Notification of cessation of securities - UBI
|
28 April 2023 at 4:10pm
|
|
March 2023 Quarterly Activity Report and Appendix 4C
|
28 April 2023 at 4:10pm
|
|
UBI launch sixth new Sentia Test
|
20 April 2023 at 8:35am
|
|
Notice of Meeting/Proxy Statement
|
11 April 2023 at 8:40am
|
|
UBI submits Xprecia Prime 510K Application to FDA
|
24 March 2023 at 11:10am
|
|
Appendix 3Y - Graham McLean
|
16 March 2023 at 9:10am
|
|
FY2022 Corporate Governance Statement & Appendix 4G
|
14 March 2023 at 12:05pm
|
|
FY2022 Corporate Governance Statement and Appendix 4G
|
24 February 2023 at 4:30pm
|
|
UBI Investor Presentation FY2022
|
24 February 2023 at 4:30pm
|
|
Appendix 4E and Annual Report on Form 10-K FY2022
|
24 February 2023 at 4:20pm
|
|
UBI launch another new Sentia Test
|
21 February 2023 at 8:55am
|
|
Change in substantial holding
|
8 February 2023 at 10:25am
|
|
UBI makes first sales of Xprecia Prime in Europe
|
6 February 2023 at 9:20am
|
|
UBI launches new product - Fructose Test for Sentia
|
30 January 2023 at 9:05am
|
|
December 2022 Quarterly Activity Report and Appendix 4C
|
27 January 2023 at 4:35pm
|
|
UBI completes Xprecia Prime clinical trial in USA
|
23 January 2023 at 10:50am
|
|
UBI appoints a new Chairman
|
16 January 2023 at 9:35am
|
|
Application for quotation of securities - UBI
|
3 January 2023 at 2:35pm
|
|
Notification of cessation of securities - UBI
|
13 December 2022 at 4:30pm
|
|
Appendix 3Y - Graham McLean
|
13 December 2022 at 4:25pm
|
|
UBI receives $3.9M under the R&D Tax Incentive Rebate
|
21 November 2022 at 1:10pm
|
|
UBI's Cancer Biomarker work gets published by ACS Sensors
|
17 November 2022 at 9:45am
|
|
Appendix 3Y - Craig Coleman
|
17 November 2022 at 9:45am
|
|
UBI Investor Presentation
|
9 November 2022 at 9:00am
|
|
Change of Registry Address
|
31 October 2022 at 4:30pm
|
|
Q3 2022 Results Presentation
|
27 October 2022 at 4:10pm
|
|
September 2022 Quarterly Activity Report and Appendix 4C
|
27 October 2022 at 4:10pm
|
|
Market Update
|
6 September 2022 at 10:30am
|
|
Change of Director's Interest Notice
|
18 August 2022 at 2:30pm
|
|
Half Year Results Presentation - 30 June 2022
|
10 August 2022 at 4:30pm
|
|
Appendix 4D and Half year Results - 30 June 2022
|
10 August 2022 at 4:05pm
|
|
New distribution deals in Europe and Glucose Test launch
|
29 July 2022 at 9:15am
|
|
June 2022 Quarterly Activity Report & Appendix 4C
|
28 July 2022 at 4:20pm
|
|
Form 605 - JM Financial Group Ltd and No Plan B Pty Ltd
|
11 July 2022 at 12:45pm
|
|
Notification of cessation of securities - UBI
|
30 June 2022 at 5:15pm
|
|
Becoming a substantial holder
|
24 June 2022 at 11:20am
|
|
Appendix 3Y - Judith Smith
|
21 June 2022 at 12:20pm
|
|
Results of 2022 Annual General Meeting
|
21 June 2022 at 12:15pm
|
|
CEO's AGM Address to Securityholders
|
21 June 2022 at 9:45am
|
|
Form 604 - JM Financial Group Ltd
|
17 June 2022 at 4:10pm
|
|
Appendix 3Y - Craig Coleman
|
17 June 2022 at 3:55pm
|
|
Ceasing to be a substantial holder
|
17 June 2022 at 10:55am
|
|
Appendix 3Y - Graham McLean
|
1 June 2022 at 5:05pm
|
|
Form 604 - Jencay Capital Pty ltd
|
31 May 2022 at 5:20pm
|
|
Form 604 - Viburnum Funds Pty Ltd
|
27 May 2022 at 5:10pm
|
Universal Biosensors, Inc